

Figure S1. Representative flow cytometry plots. (A) Human AML cell line MV4-11. The anti-hCD45-APC positive rate was 99.9%. (B) Blank control mice (without the injection of human AML cells). The anti-murine CD45-PE positive rate was 63.9%, and the anti-human CD45-APC positive rate was 0.23%. (C) Representative flow cytometry plot of OCI-AML3 mice following treatment with ABT-737 alone. (D) Vehicle control mice. The vehicle control mice were injected with  $1 \times 10^6$  MOLM-13, MV4-11, HL-60 or OCI-AML3 cells, respectively, and were treated with DMSO at a concentration of 0.001%. In the present study, anti-hCD45-APC and anti-murine CD45-PE antibodies were used to stain bone marrow cells of treated or control mice, respectively. Flow cytometry was performed to analyze the chimera rates of hCD45(+) BM cells from treated or control mice. AML, acute myeloid leukemia; APC, allophycocyanin; hCD45, human CD45; PE, phycoerythrin; -A, represented area ; Comp-, represented compensation. .

